10-Q: Tempest Therapeutics Faces Nasdaq Delisting Risk, Seeks Funding

Tempest Therapeutics' Q3 2026 report highlights substantial going concern doubts and Nasdaq listing non-compliance risks, alongside ongoing clinical development and capital-raising efforts.

Summary

• Tempest Therapeutics reported a net loss of $3.6 million for the three months ended September 30, 2026, and a net loss of $36.6 million for the nine months ended September 30, 2026.
• The company had $0.9 million in cash and cash equivalents as of September 30, 2026, raising substantial doubt about its ability to continue as a going concern.
• Tempest is actively exploring strategic alternatives and has implemented cost reductions, including workforce reductions.
• The company received notices from Nasdaq regarding non-compliance with minimum stockholders equity and minimum bid price requirements, with extensions granted to regain compliance.
• Significant capital raises occurred, including a March 2026 private placement ($2.0M gross), a May 2026 warrant inducement ($2.0M gross), an August 2026 equity line of credit ($0.3M gross as of Sept 30), and a September 2026 private placement ($2.5M gross).
• The company exercised an option to license Senlang's in vivo CAR-T technology outside Greater China, which will involve significant future payments.
• Development continues on TPST-2003 and TPST-4003, with plans for a registrational study for TPST-2003 and an investigator-initiated trial for TPST-4003 in China.
• The company incurred $22.2 million in acquired in-process research and development expenses related to the Erigen Assets acquisition.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant going concern doubts, Nasdaq non-compliance risks, and substantial accumulated deficits, despite ongoing development efforts.

Positives

• Positive interim data for TPST-2003 showed a 100% complete response rate in efficacy evaluable patients according to IMWG criteria.
• TPST-2003 demonstrated a favorable safety profile with no Grade 3 Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
• The company exercised its option to license Senlang's in vivo CAR-T technology outside Greater China, potentially expanding its pipeline.
• The company secured multiple capital raises totaling approximately $7.1 million in gross proceeds during the nine months ended September 30, 2026, with additional potential from equity lines and warrant exercises.
• Manufacturing partner Cincinnati Childrens AGCTC took delivery of the TPST-2003 lentiviral vector, supporting advancement towards a registrational study.
• Stockholder approval was obtained for issuing shares above certain limits related to the Lincoln Park ELOC and the September 2026 private placement warrants.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern, with cash and cash equivalents of $0.9 million as of September 30, 2026, expected to fund operations for less than 12 months.
• The company is not in compliance with Nasdaq's minimum stockholders equity requirement and has received a notice regarding the minimum bid price requirement, risking delisting.
• Accumulated deficit stands at $278.9 million as of September 30, 2026.
• Research and development expenses decreased significantly by 82% year-over-year for the nine months ended September 30, 2026, potentially indicating a slowdown in development activities.
• The company faces significant future payment obligations related to the Senlang license, including $10 million, $12 million, and $14 million in annual maintenance fees for the first three years.
• The company incurred $22.2 million in acquired in-process research and development expenses related to the Erigen Assets acquisition.
• The company experienced significant board and management turnover, creating continuity risks.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient cash resources.
• Failure to regain compliance with Nasdaq's minimum stockholders equity and minimum bid price requirements could lead to delisting.
• The company requires significant additional funding, and there is no assurance that such capital will be available on acceptable terms or at all.
• The company faces significant future payment obligations related to the Senlang license, including substantial annual maintenance fees and royalties.
• The company's ability to advance its clinical-stage programs and execute its business strategy may be adversely affected by management and board turnover.
• The company's product candidates may not demonstrate sufficient safety or efficacy in clinical trials, or may not receive regulatory approval.
• Competition from other biotechnology companies developing similar therapies could impact market opportunity.
• The company's ability to obtain, maintain, and enforce intellectual property rights for its product candidates is critical.

Future Outlook

The company expects to continue incurring substantial operating losses. Its existing cash is projected to fund operations for less than 12 months, necessitating further financing. Future R&D expenses are expected to increase as product candidates advance, including costs for clinical trials, regulatory support, and manufacturing. General and administrative expenses are expected to remain at approximately current levels.

Management Comments

• "We expect that our existing cash and cash equivalents will fund the Companys projected operating expense requirements through less than 12 months from the date our condensed consolidated financial statements were available to be issued."
• "Accordingly, there is substantial doubt about our ability to continue as a going concern for a period of 12 months from the date of the issuance of the Condensed Consolidated Financial Statements."
• "We are actively exploring a range of options to raise additional funds."
• "We will continue to monitor the closing bid price of our common stock and may, if appropriate, consider available options to regain compliance with the minimum bid price requirement, including initiating a reverse stock split."

Industry Context

StockSavvy.ai notes that Tempest Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector. The company's focus on in vivo CAR-T therapies for oncology and autoimmune diseases aligns with significant industry trends, but the substantial cash burn and ongoing need for capital are common challenges for companies at this stage. The Nasdaq compliance issues are also a frequent concern for smaller biotech firms.

Comparison to Industry Standards

• The company's net loss of $36.6 million for the first nine months of 2026, while substantial, is not unusual for a clinical-stage biotechnology company investing heavily in R&D. However, the low cash balance of $0.9 million raises significant concerns compared to industry peers who typically maintain larger cash reserves or have more robust, nearer-term financing in place.
• The significant decrease in R&D spending (82% for the nine months) compared to the prior year is a notable deviation from typical industry practice where R&D investment often increases as programs advance towards later-stage trials. This reduction may reflect a strategic shift or financial constraints.
• The company's efforts to raise capital through multiple private placements and an equity line of credit are standard practices in the biotech industry to fund operations and development. However, the reliance on these methods and the ongoing going concern issues suggest potential challenges in securing funding at favorable terms compared to more established companies.
• The Nasdaq listing concerns (stockholder equity and bid price) are critical. While many small-cap companies face these challenges, successful navigation often involves strategic actions like reverse stock splits or significant capital infusions, which Tempest is considering or undertaking.

Legal Proceedings

• The company is not currently a party to any material legal proceedings that, if determined adversely, would individually or taken together have a material adverse effect on its business, financial position, results of operations or cash flows.

Related Party Transactions

• The company entered into a Master Services Agreement and Work Order with Factor Bioscience Inc. (related to CEO Matt Angel) for R&D services, with a fixed fee of $5.0 million per year plus costs and a project management fee.
• The company entered into an advisory agreement with YQ Advisors Limited (related to a significant stockholder's son) for business development services, with a maximum annual aggregate amount of $720,000.
• The company settled $0.4 million in legal fees incurred by Erigen (an affiliate of Factor) with its IP counsel, WSGR, recognizing it as G&A expense.
• The company issued shares and warrants to Factor in a private placement financing in March 2026.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing equity financings and potential future warrant exercises.
• Shareholders are exposed to the risk of delisting from Nasdaq, which could negatively impact stock liquidity and market price.
• The company's going concern status and need for further capital raise may create uncertainty for investors.
• Employees may face continued uncertainty due to workforce reductions and the company's financial precariousness.

Next Steps

• Meet with the FDA to discuss initiating a U.S. registrational study for TPST-2003.
• Initiate an investigator-initiated trial (IIT) for TPST-4003 in China in approximately 10 patients with myasthenia gravis or multiple sclerosis, with first patient enrollment and dosing expected in Q4 2026.
• Continue to explore strategic alternatives to advance clinical-stage programs and maximize stockholder value.
• Seek stockholder approval for the issuance of shares related to the September 2026 private placement warrants and the Lincoln Park ELOC.
• Regain compliance with Nasdaq's minimum stockholders equity and minimum bid price requirements.

Key Dates

Recommendation

The company exhibits severe financial distress, including substantial going concern doubts and Nasdaq delisting risks. While development programs show promise, the immediate financial instability and high cash burn rate outweigh the potential upside, making it a high-risk investment. The significant dilution from ongoing capital raises further diminishes shareholder value.

Keywords

biotechnology, clinical-stage, CAR-T therapy, oncology, immunology, drug development, multiple myeloma, autoimmune disease